NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Civitas Resources, Inc. (NYSE:CIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/civitas-resources-lawsuit-submission-form?prid=148119&wire=1 or contact Joseph E. Levi, Esq.

image for news Civitas Resources, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 1, 2025 to Discuss Your Rights - CIVI

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your BigBear.ai Holdings, Inc. (NYSE:BBAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bigbear-ai-holdings-inc-lawsuit-submission-form?prid=148120&wire=1 or contact Joseph E. Levi, Esq.

image for news BBAI LAWSUIT ALERT: Levi & Korsinsky Notifies BigBear.ai Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=148121&wire=1 or contact Joseph E. Levi, Esq.

image for news Shareholders that lost money on Canopy Growth Corporation (CGC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Avis Budget Group, Inc. (NASDAQ:CAR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/avis-budget-lawsuit-submission-form?prid=148122&wire=1 or contact Joseph E. Levi, Esq.

image for news Shareholders that lost money on Avis Budget Group, Inc. (CAR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148117&wire=1 or contact Joseph E. Levi, Esq.

image for news Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148118&wire=1 or contact Joseph E. Levi, Esq.

image for news Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your SoundHound AI, Inc. (NASDAQ:SOUN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=148123&wire=1 or contact Joseph E. Levi, Esq.

image for news Shareholders of SoundHound AI, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - SOUN

H.C. Wainwright analyst Scott Buck maintained SoundHound AI Inc SOUN with a Buy and lowered the price target from $26 to $18 on Monday.

image for news SoundHound AI Expansion In Autos And Dining, Plus Q4 Profit Target, Fuels Bullish Analyst View

NEW YORK , May 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

image for news SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit

Superior Industries International, Inc. (NYSE:SUP ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Dan Lee - Senior Vice President & Chief Financial Officer Majdi Abulaban - President & Chief Executive Officer Conference Call Participants Operator Thank you for standing by. My name is Archie [ph] and I will be your conference operator today.

image for news Superior Industries International, Inc. (SUP) Q1 2025 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript — Neutral

NRXS   Seeking Alpha — May 12, 2025

NeurAxis, Inc. (NYSE:NRXS ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Ben Shamsian - IR Brian Carrico - President, CEO & Director Tim Henrichs - CFO Brian Carrico - President, CEO & Director Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the NeurAxis First Quarter 2025 Results and Update Call.

image for news NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript

ETFs on the Move Post U.S.-China Trade Deal — Positive

BNO  DUST  FNGS  GLD  IHE  PJP  PPH  USO  UUP  XPH   Zacks Investment Research — May 12, 2025

Let's delve into the ETF world following the 90-day U.S.-China trade deal.

image for news ETFs on the Move Post U.S.-China Trade Deal

Fixed income investors who want to diversify their portfolios in a challenging market environment shouldn't overlook CLOs. Danielle Gilbert, managing director at Eldridge Capital Management, discussed the value of CLOs in investment portfolios with VettaFi's Todd Rosenbluth in the recent Income Investment Strategy Symposium.

image for news Eldridge's Gilbert: CLOs “Incredibly Resilient, Often Misunderstood”

3 Reasons Why Growth Investors Shouldn't Overlook Welltower (WELL) — Positive

WELL   Zacks Investment Research — May 12, 2025

Welltower (WELL) possesses solid growth attributes, which could help it handily outperform the market.

image for news 3 Reasons Why Growth Investors Shouldn't Overlook Welltower (WELL)

3 Reasons Why Growth Investors Shouldn't Overlook AppLovin (APP) — Positive

APP   Zacks Investment Research — May 12, 2025

AppLovin (APP) possesses solid growth attributes, which could help it handily outperform the market.

image for news 3 Reasons Why Growth Investors Shouldn't Overlook AppLovin (APP)

Nova Ltd. (NVMI) is an Incredible Growth Stock: 3 Reasons Why — Positive

NVMI   Zacks Investment Research — May 12, 2025

Nova Ltd. (NVMI) could produce exceptional returns because of its solid growth attributes.

image for news Nova Ltd. (NVMI) is an Incredible Growth Stock: 3 Reasons Why

Is New Jersey Resources (NJR) a Solid Growth Stock? 3 Reasons to Think "Yes" — Positive

NJR   Zacks Investment Research — May 12, 2025

New Jersey Resources (NJR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

image for news Is New Jersey Resources (NJR) a Solid Growth Stock? 3 Reasons to Think "Yes"

Here is Why Growth Investors Should Buy Lam Research (LRCX) Now — Positive

LRCX   Zacks Investment Research — May 12, 2025

Lam Research (LRCX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

image for news Here is Why Growth Investors Should Buy Lam Research (LRCX) Now

3 Reasons Growth Investors Will Love Phibro (PAHC) — Positive

PAHC   Zacks Investment Research — May 12, 2025

Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

image for news 3 Reasons Growth Investors Will Love Phibro (PAHC)

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) — Positive

HALO   Zacks Investment Research — May 12, 2025

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

image for news 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)